Disc Medicine (NASDAQ:IRON) Price Target Raised to $75.00

Disc Medicine (NASDAQ:IRON) had its price objective boosted by Scotiabank from $73.00 to $75.00 in a research report report published on Monday,Benzinga reports. They currently have a sector outperform rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. TD Cowen began coverage on shares of Disc Medicine in a research report on Thursday, February 27th. They set a “buy” rating for the company. Morgan Stanley raised shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective for the company in a research report on Tuesday, November 5th. HC Wainwright reissued a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Stifel Nicolaus boosted their price objective on shares of Disc Medicine from $90.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Finally, Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and boosted their price objective for the company from $66.00 to $110.00 in a research report on Monday, November 4th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $89.10.

Disc Medicine Trading Up 2.9 %

NASDAQ:IRON opened at $56.92 on Monday. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $70.54. The company has a market cap of $1.69 billion, a PE ratio of -14.30 and a beta of 0.73. The company has a 50 day simple moving average of $57.54 and a two-hundred day simple moving average of $55.76.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.08. Research analysts forecast that Disc Medicine will post -4.07 earnings per share for the current year.

Insider Activity at Disc Medicine

In related news, CEO John D. Quisel sold 12,791 shares of Disc Medicine stock in a transaction on Monday, December 16th. The shares were sold at an average price of $66.01, for a total transaction of $844,333.91. Following the transaction, the chief executive officer now owns 72,065 shares in the company, valued at approximately $4,757,010.65. The trade was a 15.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $55.54, for a total transaction of $416,550.00. Following the transaction, the insider now owns 14,035 shares in the company, valued at approximately $779,503.90. This trade represents a 34.83 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 74,080 shares of company stock worth $4,523,520. 4.24% of the stock is owned by corporate insiders.

Institutional Trading of Disc Medicine

Several hedge funds have recently bought and sold shares of IRON. FMR LLC lifted its stake in Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company’s stock worth $118,320,000 after purchasing an additional 1,459,434 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Disc Medicine by 62.4% in the 4th quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after purchasing an additional 467,988 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Disc Medicine by 23.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock worth $88,421,000 after purchasing an additional 262,690 shares in the last quarter. State Street Corp lifted its stake in Disc Medicine by 39.7% in the 3rd quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after purchasing an additional 235,115 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Disc Medicine in the 4th quarter worth $5,579,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.